MAPK1 and cancer: Low levels of miR-508/miR-18a and increased expression of MAPK1 and ERK were identified in ovarian cancer, while miR-508 mimics were found to repress MAPK1 and ERK, resulting in suppression of EMT and the malignant progression of cancer cells [148, 149].